PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
02-May-2022 Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit Businesswire
02-May-2022 Akanda Completes Acquisition of Holigen, Advancing Cannabis Leadership Position in Europe, the Middle East and Africa (EMEA) Businesswire
02-May-2022 Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) Businesswire
02-May-2022 Energous Adds Three Industry Veterans to Board of Advisors as Company Focuses on Powering the Growing Industrial and Retail Internet of Things Ecosystem Businesswire
02-May-2022 FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates Businesswire
02-May-2022 OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy Businesswire
02-May-2022 NEXEL Earns the First ISO/IEC 17025:2017 Accreditation for iPSC-derived Cardiomyocyte-based Cardiac Safety Testing Businesswire
02-May-2022 Europäische Kommission erteilt UPLIZNA® (Inebilizumab) die Zulassung zur Behandlung von Erwachsenen mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) Businesswire
02-May-2022 Horizon Therapeutics plc reçoit l’approbation de la Commission européenne (CE) pour UPLIZNA® (inébilizumab) dans le traitement des adultes atteints de troubles du spectre de la neuromyélite optique (NMOSD) Businesswire
02-May-2022 Horizon Therapeutics riceve l’approvazione della Commissione europea (CE) per inebilizumab per il trattamento di adulti affetti da disturbo dello spettro della neuromielite ottica (NMOSD) Businesswire
02-May-2022 Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Businesswire
28-Apr-2022 AARDEX® Group adds etectRx to their MEMS® Adherence Hardware ecosystem AARDEX® Group
26-Apr-2022 Concentric Health Experience Named Agency of the Year at the 2022 Manny Awards Newswire
25-Apr-2022 Tower Cold Chain wins Queen’s Award for International Trade Tower Cold Chain
25-Apr-2022 Microbiologics Acquires Cryologics Newswire
25-Apr-2022 Pano Therapeutics, Inc. Announces the Strategic Acquisition of NovaTarg Therapeutics, Inc. and the Appointment of Ken Batchelor, PhD, as Head of Research & Development Newswire
22-Apr-2022 SERUM X - a New, Innovative Form of Topical Pain Relief With Powerful Super-Antioxidant Action From New Biotech AO Biologix Newswire
21-Apr-2022 Cardiff-Based CatSci Win Prestigious The Queen's Awards For Enterprise: International Trade 2022 CatSci Ltd
21-Apr-2022 Evaluate announces global strategic collaboration with Treehill Partners Evaluate
20-Apr-2022 InvestChile Promotes Pharmaceutical Companies Landing in South America's Business Hub Newswire